PKAN (Pantothenate Kinase-Associated Neurodegeneration) is the most common form of NBIA (Neurodegeneration with Brain Iron Accumulation), accounting for 35-50% of all cases. It is caused by autosomal recessive mutations in the PANK2 gene (pantothenate kinase 2), which catalyzes the rate-limiting first step of coenzyme A (CoA) biosynthesis. The resulting CoA deficiency causes mitochondrial dysfunction, impaired fatty acid metabolism, and characteristic iron accumulation in the globus pallidus — visible as the pathognomonic "eye of the tiger" sign on MRI[@zhou2020][@hoglinger2021].
¶ Genetics and Inheritance
| Feature |
Detail |
| Gene |
PANK2 (Pantothenate Kinase 2) on chromosome 17p11.2 |
| Inheritance |
Autosomal recessive |
| Mutation spectrum |
Missense (late-onset), nonsense/frameshift (classic/early-onset) |
| Protein |
Pantothenate kinase 2 (mitochondrial matrix enzyme) |
| Substrate |
Vitamin B5 (pantothenate) → phosphopantothenate |
PANK2 is a mitochondrial matrix enzyme that catalyzes the phosphorylation of pantothenate (vitamin B5) to phosphopantothenate — the first and rate-limiting step of the five-step CoA biosynthesis pathway. Patients with classic PKAN typically have complete or near-complete loss of PANK2 activity, while late-onset forms retain partial activity.
flowchart TD
A["PANK2 Biallelic Mutation"] --> B["Loss of Pantothenate Kinase 2 Activity"]
B --> C["Decreased Phosphopantothenate Production"]
C --> D["Impaired CoA Biosynthesis Pathway"]
D --> E1["Reduced Cellular CoA Pool"]
D --> E2["Accumulation of Pantothenate Upstream"]
D --> E3["Deficiency of Acyl Carrier Protein Activation"]
E1 --> F1["Mitochondrial Dysfunction"]
E1 --> F2["Impaired Fatty Acid Beta-Oxidation"]
E1 --> F3["Reduced Protein Acetylation"]
F1 --> G1["Increased Mitochondrial Iron Uptake"]
F1 --> G2["Oxidative Phosphorylation Deficit"]
F2 --> G3["Lipid Accumulation in Neurons"]
G3 --> G1
G1 --> H["Iron Accumulation in Globus Pallidus"]
G2 --> H
H --> I["Fenton Chemistry and ROS Generation"]
I --> J["Lipid Peroxidation and Protein Oxidative Damage"]
J --> K["Neuronal Death in GP and SNr"]
E3 --> K
K --> L["Movement Disorder Phenotype"]
L --> M["Dystonia"]
L --> N["Parkinsonism (rigidity, bradykinesia)"]
L --> O["Spasticity"]
L --> P["Iron Retinitis Pigmentosa"]
style L fill:#f3e5f5,stroke:#333,stroke-width:2px
style A fill:#ffcdd2,stroke:#333
CoA is synthesized in five enzymatic steps:
- PANK2 (Step 1): Pantothenate → Phosphopantothenate (rate-limiting)
- PPCS (Step 2): Phosphopantothenate → Phosphopantothenoylcysteine
- PPCDC (Step 3): Phosphopantothenoylcysteine → Pantetheine-4-phosphate
- COASY (Step 4): Pantetheine-4-phosphate → Dephospho-CoA
- COASY (Step 5): Dephospho-CoA → CoA
PANK2 deficiency blocks the first step, causing 50-90% reduction in cellular CoA in affected tissues[@leonardi2019].
The globus pallidus internus (GPi) and substantia nigra pars reticulata (SNr) are preferentially vulnerable in PKAN because:
- Highest neuronal energy demand in the basal ganglia
- High iron content relative to other brain regions
- GABAergic neurons with high mitochondrial density — most sensitive to CoA deficit
- Progressive neuronal death in these regions causes the characteristic movement disorder
The MRI finding of central T2 hyperintensity surrounded by T2 hypointensity in the GP reflects:
- Central zone: glial reaction and tissue vacuolization
- Peripheral zone: iron deposition (hemosiderin)
- This pattern appears early and is highly specific for PKAN among NBIA subtypes
| Feature |
Classic PKAN |
Atypical/Late-Onset PKAN |
| Age of onset |
3-12 years |
Adolescence to adulthood |
| Initial symptoms |
Gait disorder, dystonia |
Dystonia, dysarthria, gait difficulties |
| Progression |
Rapid (loss of ambulation in 5-10 years) |
Slower (15+ years to disability) |
| Eye of the tiger |
Usually present |
Often absent or subtle |
| Retinitis pigmentosa |
Common |
Less common |
| Pyramidal signs |
Common |
Variable |
| Cognitive decline |
Progressive |
Mild-to-moderate |
| Approach |
Status |
Evidence |
| Pantethine (vitamin B5 derivative) |
Active trials |
Bypasses defective PANK2; some benefit in late-onset[@collins2022] |
| Phosphopantetheine (PPE) |
Investigational |
Directly replaces the product of the PANK2 step[@patel2024] |
| CoA supplementation |
Limited |
CoA does not cross BBB efficiently |
| Deep brain stimulation (DBS) |
Used for severe dystonia |
GPi-DBS shows benefit in selected cases |
| Iron chelation |
Not standard |
Iron is secondary; clinical benefit unclear |
| Physical/occupational therapy |
Standard of care |
Maintains function |
- PANTOPAN study (NCT05194109): Phosphopantetheine supplementation trial
- AAV-PANK2 gene therapy: Preclinical studies in mouse models
- Small molecule PANK2 activators: Compounds to enhance residual enzyme activity
- CoA prodrugs with BBB penetration: Designed to restore CNS CoA levels
Unlike other neurodegenerative disorders where iron accumulation is primary, PKAN patients may benefit from metabolic supplementation because the upstream block (pantothenate → phosphopantothenate) is bypassable with downstream intermediates. This makes PKAN a uniquely treatable NBIA subtype.
- Zhou X, et al., PANK2 mutations and phenotype in pantothenate kinase-associated neurodegeneration (Neurology, 2020)
- Hayflick SJ, et al., Genetic, clinical, and radiographic delineation of PKAN (Brain, 2013)
- Hoglinger GU, et al., Consensus clinical management guideline for PKAN (Movement Disorders, 2021)
- Arber CE, et al., Investigational therapeutics for PKAN (Developmental Medicine, 2021)
- Chung J, et al., PKAN: new insights into pathogenesis and therapeutic approaches (Brain, 2023)
- Leonardi R, et al., Coenzyme A biosynthesis: implications for brain function (Journal of Inherited Metabolic Disease, 2019)
- Collins J, et al., Pantethine Therapy in PKAN (Journal of Inherited Metabolic Disease, 2022)
- Patel S, et al., Phosphopantetheine therapy for PKAN (Molecular Genetics, 2024)
- Santambrogio N, et al., Mitochondrial dysfunction in PKAN (Human Molecular Genetics, 2015)
- Worsley CE, et al., Brain iron accumulation in NBIA disorders (Radiology, 2022)